In addition, the use of Claudin-1-specific monoclonal antibodies in renal, hepatic, and lung fibrosis models showed clear antifibrotic effects, further indicating the role of Claudin-1 as a therapeutic target for tissue fibrosis across organs [25]. Here, CLDN1 is linked to pulmonary fibrosis.